![FDA, FTC and DOJ Enforcement of Medical Device Regulations FDA, FTC and DOJ Enforcement of Medical Device Regulations](https://www.fdanews.com/ext/resources/Book-Covers-2/BFFDEMDR-COVER.png?height=200&t=1685733565&width=200)
Home » Elscint Holding Gamida-Cell, Teva to Develop and Commercialize StemEx
Elscint Holding Gamida-Cell, Teva to Develop and Commercialize StemEx
Elscint Ltd. announced that Teva Pharmaceutical Industries
Ltd. has exercised its option to enter into a joint venture with Gamida-Cell
Ltd., in which Elscint (through a wholly owned subsidiary) holds 29.2 percent
on a fully diluted basis, in order to develop and commercialize StemEx for the
treatment of Leukemia and Lymphoma.
Yahoo
News
KEYWORDS FDAnews Drug Daily Bulletin
Upcoming Events
-
11Jul
-
18Jul
-
21Oct